Chinese instructions for Blinatumomab

1. Indications:

Blinatumomab (Blinatumomab) is a biologic agent suitable for the treatment of patients with acute lymphoblastic leukemia (ALL). Specifically, it is used primarily in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), especially those who have developed resistance to traditional treatments.

2. Mechanism of action:

Belintuzumab's mechanism of action is based on its bispecific antibody structure. It binds to CD3positiveT cells at one end, and binds to CD19positiveB cells at the other end. This allows bellintuzumab to connect with the T cells and the B-ALL cells, directing the T cells to attack the leukemia cells. By releasing cytotoxic mediators, belintuzumab helps T cells destroy B-ALL cells to achieve therapeutic effects.

3. Pharmacology:

The pharmacological characteristics of belintuzumab are its targeting and antigen specificity. Its targeted nature reduces unnecessary damage to normal cells and improves the safety of treatment. Pharmacological studies have shown that belintuzumab's mechanism of action helps achieve high response rates and longer remission periods while maintaining patients' immune system function.

4. Dosage and usage:

Belintuzumab is usually given by intravenous injection. The specific arrangement of the treatment cycle should be determined according to the doctor's prescription and the patient's condition. Typically, a treatment cycle includes multiple injections of medication, with a rest period between each cycle. The specific schedule and number of cycles of treatment will vary depending on the patient's disease and response to treatment.

5. Side effects:

Belintuzumab treatment may be associated with some side effects, including: fever, headache, nausea, cough, muscle or joint pain, anemia, leukopenia, etc.

Some patients may experience more serious adverse reactions, such as cytotoxic reactions, neurological reactions, pulmonary edema, etc. The course of treatment requires close monitoring and management, as well as the provision of supportive care.

6. Warnings and Precautions:

Patients need to be closely monitored and follow their physician's recommendations while receiving belintuzumab. Things that need special attention include:

Monitor blood levels regularly to check for possible cytopenias.

Exposure to sources of infection needs to be avoided because treatment may reduce immune system function.

Regularly check liver and kidney function to ensure drug safety.

7. Contraindications:

Belintuzumab may not be suitable for use in certain circumstances, including in patients who are allergic to components of the drug and in patients with severe allergic reactions. The patient's contraindications should be discussed in detail with the doctor before treatment.

8. Drug interactions:

Belintuzumab may interact with other medications, so patients need to inform their doctor of all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements, before receiving treatment.

9. Drugs for special groups:

For special populations, such as children, the elderly, and pregnant women, the use of belintuzumab requires careful decision-making based on their specific circumstances. In these cases, doctors will evaluate the potential benefits and risks to determine the most appropriate treatment options.

Belintuzumab represents an advanced concept of targeted therapy and provides a new treatment option for patients with acute lymphoblastic leukemia. However, patients should fully understand this drug before receiving treatment and work closely with their doctor to ensure safe and effective treatment.